<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01336153</url>
  </required_header>
  <id_info>
    <org_study_id>RN89-01-117-7548</org_study_id>
    <nct_id>NCT01336153</nct_id>
  </id_info>
  <brief_title>Clinical Study to Investigate the Safety and Efficacy of MLC601 in 150 Iranian Patients After Stroke</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shahid Beheshti University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shahid Beheshti University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shahid Beheshti University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the safety and efficacy of MLC601 (NeuroAideTM) as a Traditional Chinese
      Medicine on motor recovery after ischemic stroke.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a double-blind, placebo-controlled clinical trial study on 150 patients with a recent
      (less than 3 month) ischemic stroke. All patients will give either MLC601 (100 patients) or
      placebo (50 patients), 4 capsules 3 times a day, as an add-on to standard medication of post
      stroke for 3 months. Motor improvement will be monitored using Fugl-Meyer Assessment FMA.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2009</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Investigate the Safety and Efficacy of MLC601</measure>
    <time_frame>18 months</time_frame>
    <description>Patients showed a good tolerability to treatment and adverse events were mild and transient.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Motor recovery of MLC601 in 150 Iranian Patients after Stroke</measure>
    <time_frame>18 months</time_frame>
    <description>Repeated measured analysis showed statistically difference in Fugl-Meyer Assessment FMA score during 12 months between two groups</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Stroke</condition>
  <arm_group>
    <arm_group_label>MLC601</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MLC601 (NeuroAideTM) is a TCM which is used extensively in China to improve recovery after stroke. It combines several herbal and animal components.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MLC601</intervention_name>
    <description>group A (100 patients; NeuroAid 400mg, 4 capsules 3 times daily) or for 3 month</description>
    <arm_group_label>MLC601</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>group B (50 patients; placebo, 4 capsules 3 times daily) for 3 months</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age between 30-72 yars,

          -  &lt; one month after stroke,

          -  ischemic cerebral stroke,

          -  signed informed consent form.

        Exclusion Criteria:

          -  treatment with thrombolytic after stoke,

          -  ischemic stroke combined with hemorrhage, severe renal or liver failure, dementia,
             psychosis and history of seizure disorder, history of previous stroke, and hemoglobin
             level less than 10mg/dl on admission.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>72 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>December 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 13, 2011</study_first_submitted>
  <study_first_submitted_qc>April 14, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 15, 2011</study_first_posted>
  <last_update_submitted>April 29, 2011</last_update_submitted>
  <last_update_submitted_qc>April 29, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 2, 2011</last_update_posted>
  <responsible_party>
    <name_title>Mostafa Ghanei</name_title>
    <organization>Ministry of Health</organization>
  </responsible_party>
  <keyword>Safety</keyword>
  <keyword>Efficacy</keyword>
  <keyword>MLC601</keyword>
  <keyword>motor recovery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

